Literature DB >> 24900656

Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.

Takaaki Sumiyoshi1, Takeshi Enomoto1, Kentaro Takai1, Yoko Takahashi1, Yasuko Konishi1, Yoshiharu Uruno1, Kengo Tojo1, Atsushi Suwa1, Harumi Matsuda1, Tomokazu Nakako1, Mutsuko Sakai1, Atsushi Kitamura1, Yasuaki Uematsu1, Akihiko Kiyoshi1.   

Abstract

Activation of the M1 and M4 muscarinic acetylcholine receptors is thought to play an important role in improving the symptoms of schizophrenia. However, discovery of selective agonists for these receptors has been a challenge, considering the high sequence homology and conservation of the orthosteric acetylcholine binding site among muscarinic acetylcholine receptor subtypes. We report in this study the discovery of novel N-substituted oxindoles as potent muscarinic acetylcholine receptor partial agonists selective for M1 and M4 over M2, M3, and M5. Among these oxindoles, compound 1 showed high selectivity for the M1 and M4 receptors with remarkable penetration into the central nervous system. Compound 1 reversed methamphetamine- and apomorphine-induced psychosis-like behaviors with low potency to extrapyramidical and peripheral side effects.

Entities:  

Keywords:  muscarinic acetylcholine receptor; oxindole; partial agonist; schizophrenia; selective agonist

Year:  2013        PMID: 24900656      PMCID: PMC4027492          DOI: 10.1021/ml300372f

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  26 in total

1.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 2.  Section I. The cholinergic system.

Authors:  John Smythies
Journal:  Int Rev Neurobiol       Date:  2005       Impact factor: 3.230

Review 3.  Molecular biology of muscarinic acetylcholine receptors.

Authors:  J Wess
Journal:  Crit Rev Neurobiol       Date:  1996

Review 4.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

5.  Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.

Authors:  Celine Valant; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2011-10-11       Impact factor: 4.436

6.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Authors:  N C Bodick; W W Offen; A I Levey; N R Cutler; S G Gauthier; A Satlin; H E Shannon; G D Tollefson; K Rasmussen; F P Bymaster; D J Hurley; W Z Potter; S M Paul
Journal:  Arch Neurol       Date:  1997-04

7.  The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.

Authors:  K J Stanhope; N R Mirza; M J Bickerdike; J L Bright; N R Harrington; M B Hesselink; G A Kennett; S Lightowler; M J Sheardown; R Syed; R L Upton; G Wadsworth; S M Weiss; A Wyatt
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

8.  Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.

Authors:  C J Langmead; N E Austin; C L Branch; J T Brown; K A Buchanan; C H Davies; I T Forbes; V A H Fry; J J Hagan; H J Herdon; G A Jones; R Jeggo; J N C Kew; A Mazzali; R Melarange; N Patel; J Pardoe; A D Randall; C Roberts; A Roopun; K R Starr; A Teriakidis; M D Wood; M Whittington; Z Wu; J Watson
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

9.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Authors:  Anantha Shekhar; William Z Potter; Jeffrey Lightfoot; John Lienemann; Sanjay Dubé; Craig Mallinckrodt; Frank P Bymaster; David L McKinzie; Christian C Felder
Journal:  Am J Psychiatry       Date:  2008-07-01       Impact factor: 18.112

10.  Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Authors:  James C Tarr; Mark L Turlington; Paul R Reid; Thomas J Utley; Douglas J Sheffler; Hyekyung P Cho; Rebecca Klar; Tristano Pancani; Michael T Klein; Thomas M Bridges; Ryan D Morrison; Anna L Blobaum; Zixui Xiang; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Michael R Wood; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2012-07-18       Impact factor: 4.418

View more
  1 in total

Review 1.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.